WHO publishes guidelines for the treatment of hepatitis C
Hepatitis C is a contagious liver disease that results from infection with hepatitis C virus (HCV). It can range in severity from a mild illness lasting a few weeks to a serious, lifelong illness. According More...
FDA grants Bristol-Myers Squibb ‘Breakthrough Therapy Designation’ for investigational HCV regimen
Bristol-Myers Squibb Company today announced that the U.S. Food and Drug Administration (FDA) has granted its investigational DCV Dual Regimen (daclatasvir and asunaprevir) Breakthrough Therapy Designation for More...
Hepatitis C drug, Sovaldi, receives FDA nod
The U.S. Food and Drug Administration (FDA) approved Sovaldi (sofosbuvir) to treat chronic hepatitis C virus (HCV) infection yesterday. Sovaldi is the first drug that has demonstrated safety and efficacy to treat More...
FDA approves Olysio to treat chronic hepatitis C
The U.S. Food and Drug Administration yesterday approved Olysio (simeprevir), a new therapy to treat chronic hepatitis C virus infection. Image/Video Screen Shot Hepatitis C is a viral disease that causes inflammation More...
FDA approves Promacta to treat low platelet counts in hepatitis C patients
The U.S. Food and Drug Administration (FDA) has approved PROMACTA for the treatment of thrombocytopenia (low blood platelet counts) in patients with chronic hepatitis C to allow them to initiate and maintain interferon-based More...
